Brief: Takeda Pharmaceutical Conducted Thorough Assessment, Found There Was No Confirmed Causal Relationship To Use Of Adzynma &Patient Death - Spokesperson
Nov 21 (Reuters) - Takeda Pharmaceutical Co Ltd 4502.T: TAKEDA PHARMACEUTICAL: CONDUCTED THOROUGH ASSESSMENT, FOUND THERE WAS NO CONFIRMED CAUSAL RELATIONSHIP TO USE OF ADZYNMA &PATIENT DEATH - SPOKESPERSON Further company coverage: 4502.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Takeda Pharmaceutical
See all newsFactbox: Pharma sector doubles down on AI to slash costs, timelines
Nvidia-backed Iambic Therapeutics tumbles below IPO price
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Nvidia-backed Iambic Therapeutics launches IPO as biotechs buck market gloom (updated)